Posts by: Marta Figueiredo

Marta Figueiredo

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

August 19, 2019September 4, 2019

Abnormal Blood Pressure Patterns May Predict Cardiovascular Disease in Juvenile-onset SLE, Ongoing Study Suggests

News

Abnormal blood pressure patterns during sleep and overall high blood pressure may independently predict cardiovascular disease in patients with juvenile-onset systemic lupus erythematosus (JSLE), according to a recent update on ... Read more

October 10, 2018October 10, 2018

Childhood SLE Has Major Impact in Adulthood, Dutch Study Shows

News

People with childhood-onset systemic lupus erythematosus (cSLE) develop significant disease-associated damage early in life and have lower quality of life in their adulthood, without achieving medication-free remission, according to a ... Read more

September 19, 2018September 19, 2018

Depression May Increase Risk of Developing Lupus, Long-term Study Shows

News

Women with a history of depression have more than twice the risk of developing systemic lupus erythematosus (SLE), according to a two-decade prospective study from Harvard. The study, “Association of Depression ... Read more

September 12, 2018September 12, 2018

Transplantation of Placenta Cells May Halt Inflammation in Lupus Patients, Mouse Study Suggests

News

The transplantation of human placental cells was found to suppress immune and inflammatory responses in a mouse model of systemic lupus erythematosus (SLE), suggesting a potential new therapeutic strategy for lupus, ... Read more

April 27, 2018

Subcutaneous Benlysta Reduces Disease Activity in Subset of Lupus Patients, Analysis Shows

News

Benlysta (belimumab) reduces disease activity, relapses, and the need for corticosteroids in patients with a high degree of systemic lupus erythematosus (SLE) disease activity, according to a new analysis of a ... Read more

April 23, 2018April 23, 2018

Add-on Lupuzor Fails Primary Goal but Shows Some Positive Results in Phase 3 Trial for SLE

News

Lupuzor (rigerimod, or IPP-201101) combined with standard therapy did not demonstrate a statistically significant response rate in systemic lupus erythematosus (SLE) patients over standard care alone, failing the primary goal of a ... Read more